Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 2/20 | 0.42 |
| ▸ | MAP2K1 | Q02750 | 2/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.42 |
| ▸ | JAK2 | O60674 | 1/20 | 0.42 |
| ▸ | KDR | P35968 | 1/20 | 0.42 |
| ▸ | GSK3A | P49840 | 1/20 | 0.42 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.42 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.42 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.42 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.42 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.42 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 4/20 | 0.40 |
| ▸ | RAB9A | P51151 | 4/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.40 |
| ▸ | RELA | Q04206 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL116392 | 0.85 | — | — | |
| SCHEMBL30462623 | 0.85 | — | — | |
| Bromide SCHEMBL25319134 | 0.83 | CYP11B1 (0.44) | CYP2E1CYP2A6CYP2B6CYP11B1CYP11B2 | |
| SCHEMBL15304176 | 0.83 | RAB9A (0.58) | RETMAP2K1MAPK14JAK2KDR | |
| SCHEMBL19925525 | 0.83 | KDM1A (0.43) | RETMAP2K1MAPK14JAK2KDR | |
| SCHEMBL6910763 | 0.79 | SMN1; SMN2 (0.43) | RETMAP2K1MAPK14NPC1RAB9A | |
| SCHEMBL29574545 | 0.77 | CCR1 (0.40) | NPC1RAB9ASMN1; SMN2NFKB1MAPK1 | |
| SCHEMBL2891450 | 0.77 | CCR1 (0.40) | NPC1RAB9ASMN1; SMN2NFKB1MAPK1 | |
| SCHEMBL9805438 | 0.77 | RAB9A (0.63) | RETMAP2K1MAPK14NPC1RAB9A | |
| SCHEMBL507838 | 0.75 | CYP11B1 (0.47) | RETMAP2K1MAPK14NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11040026-B2 | Muscarinic M1 receptor positive allosteric modulators | SUVEN LIFE SCIENCES LIMITED (IN) | 2021-06-22 | — | — | US | disclosed |
| EP-3507289-B1 | MUSCARINIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | SUVEN LIFE SCIENCES LTD (IN) | 2020-07-15 | — | — | EP | disclosed |
| EP-3507289-B1 | MUSCARINIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | SUVEN LIFE SCIENCES LTD (IN) | 2020-07-15 | — | — | EP | disclosed |
| US-20190343812-A1 | MUSCARINIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | SUVEN LIFE SCIENCES LIMITED (IN) | 2019-11-14 | — | — | US | disclosed |
| WO-2018042362-A1 | MUSCARINIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | SUVEN LIFE SCIENCES LIMITED (IN) | 2018-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11040026-B2 | Muscarinic M1 receptor positive allosteric modulators | CHRM1, CHRM2, CHRM3 | RET 786/4885MAP2K1 1641/4885MAPK14 1846/4885 |
| US-20190343812-A1 | MUSCARINIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | CHRM1, CHRM2, CHRM3 | RET 786/4885MAP2K1 1641/4885MAPK14 1846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.